🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
547,09 USD
Máx. histórico
558,88
7 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,11%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+0,85%
Cierre anterior
542,50
Rango de hoy
531,53 – 548,76
Volumen hoy
1.271.214
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 35,21 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 2 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 24/10/2006 | 33,49 | 33,87 | 32,50 | 33,32 | -1,10% | 4,09% | 1.558.500 |
| 23/10/2006 | 34,04 | 34,15 | 32,95 | 33,69 | -1,35% | 3,53% | 2.285.400 |
| 20/10/2006 | 36,38 | 36,46 | 34,00 | 34,15 | -5,77% | 6,76% | 5.037.700 |
| 19/10/2006 | 36,56 | 36,97 | 36,08 | 36,24 | +0,19% | 2,43% | 1.354.800 |
| 18/10/2006 | 36,19 | 37,16 | 35,91 | 36,17 | +0,08% | 3,45% | 1.066.400 |
| 17/10/2006 | 36,49 | 36,79 | 35,54 | 36,14 | -1,71% | 3,43% | 1.474.000 |
| 16/10/2006 | 36,00 | 36,94 | 35,64 | 36,77 | +1,88% | 3,61% | 952.300 |
| 13/10/2006 | 36,32 | 36,36 | 35,30 | 36,09 | -0,55% | 2,92% | 1.424.600 |
| 12/10/2006 | 35,78 | 36,40 | 35,53 | 36,29 | +1,43% | 2,43% | 821.100 |
| 11/10/2006 | 35,81 | 36,58 | 35,12 | 35,78 | -0,91% | 4,08% | 1.165.100 |
| 10/10/2006 | 36,80 | 37,93 | 34,95 | 36,11 | -2,80% | 8,10% | 2.384.900 |
| 09/10/2006 | 36,47 | 37,35 | 36,25 | 37,15 | +1,20% | 3,02% | 996.600 |
| 06/10/2006 | 36,79 | 37,00 | 36,00 | 36,71 | -0,22% | 2,72% | 1.583.000 |
| 05/10/2006 | 34,72 | 36,99 | 34,53 | 36,79 | +5,48% | 7,09% | 2.198.000 |
| 04/10/2006 | 33,88 | 34,90 | 33,85 | 34,88 | +2,62% | 3,10% | 1.049.300 |
| 03/10/2006 | 34,00 | 34,81 | 33,28 | 33,99 | -0,21% | 4,50% | 1.375.900 |
| 02/10/2006 | 33,50 | 34,58 | 33,33 | 34,06 | +1,22% | 3,73% | 2.078.500 |
| 29/09/2006 | 33,52 | 33,78 | 32,76 | 33,65 | +0,78% | 3,04% | 1.638.800 |
| 28/09/2006 | 34,15 | 34,41 | 33,05 | 33,39 | +1,99% | 3,98% | 1.916.400 |
| 27/09/2006 | 31,90 | 32,96 | 31,71 | 32,74 | +3,15% | 3,92% | 1.480.400 |
| 26/09/2006 | 31,70 | 31,80 | 31,47 | 31,74 | +0,28% | 1,04% | 1.450.600 |
| 25/09/2006 | 31,60 | 32,21 | 31,40 | 31,65 | -0,16% | 2,56% | 1.574.200 |
| 22/09/2006 | 32,69 | 32,94 | 31,61 | 31,70 | -3,44% | 4,07% | 1.480.600 |
| 21/09/2006 | 33,20 | 33,50 | 32,25 | 32,83 | -1,26% | 3,77% | 978.800 |
| 20/09/2006 | 33,15 | 33,60 | 32,76 | 33,25 | +3,20% | 2,53% | 2.290.400 |
| 19/09/2006 | 32,47 | 32,92 | 32,19 | 32,22 | -1,17% | 2,25% | 1.313.000 |
| 18/09/2006 | 33,11 | 33,11 | 32,30 | 32,60 | -1,15% | 2,45% | 1.567.000 |
| 15/09/2006 | 33,84 | 33,90 | 32,63 | 32,98 | -1,61% | 3,75% | 5.791.600 |
| 14/09/2006 | 34,10 | 34,42 | 33,50 | 33,52 | -2,39% | 2,70% | 1.236.000 |
| 13/09/2006 | 34,38 | 34,39 | 33,41 | 34,34 | -0,72% | 2,85% | 1.661.900 |